Dissecting Out a Rare Mutation, STAT: Features of STAT3-Mutant Myeloid Neoplasms DOI
Michael J. Hochman, David A. Frank

Clinical Cancer Research, Journal Year: 2024, Volume and Issue: 30(20), P. 4554 - 4556

Published: Aug. 7, 2024

The transcription factor STAT3 drives the expression of genes promoting cellular proliferation, survival, and pluripotency. description mutations their clinical correlates in myeloid neoplasms, such as acute leukemia myelodysplastic syndromes, raises new insights into both pathogenesis targeted therapy these diseases. See related article by Ye et al., p. 4681.

Language: Английский

Immunocytes interact directly with cancer cells in the tumor microenvironment: one coin with two sides and future perspectives DOI Creative Commons
Zhiyi Ye, Pu Cheng, Qi Huang

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: May 22, 2024

The tumor microenvironment is closely linked to the initiation, promotion, and progression of solid tumors. Among its constitutions, immunologic cells emerge as critical players, facilitating immune evasion progression. Apart from their indirect impact on anti-tumor immunity, immunocytes directly influence neoplastic cells, either bolstering or impeding advancement. However, current therapeutic modalities aimed at alleviating immunosuppression regulatory effector cell populations may not consistently yield satisfactory results in various tumors, such breast carcinoma, colorectal cancer, etc. Therefore, this review outlines summarizes direct, dualistic effects T innate lymphoid B eosinophils, tumor-associated macrophages within microenvironment. also delves into underlying mechanisms involved presents outcomes clinical trials based these direct effects, aiming propose innovative efficacious strategies for addressing

Language: Английский

Citations

5
STAT signaling in the pathogenesis and therapy of acute myeloid leukemia and myelodysplastic syndromes DOI Creative Commons

Zoe King,

Sudhamsh Reddy Desai, David A. Frank

et al.

Neoplasia, Journal Year: 2025, Volume and Issue: 61, P. 101137 - 101137

Published: Feb. 10, 2025

Language: Английский

Citations

0
Supercharging CAR-T cells through transcriptional and epigenetic armoring DOI Creative Commons
Diyuan Qin,

Yanna Lei,

Pei Shu

et al.

Theranostics, Journal Year: 2025, Volume and Issue: 15(8), P. 3345 - 3367

Published: Feb. 18, 2025

Inspired by the remarkable success of CAR-T therapy in hematologic malignancies, research is increasingly focused on adapting this treatment for solid tumors. However, efficacy remains limited due to its exhaustion and shortened persistence. Transcription factors epigenetic modifications play pivotal roles modulating T cell differentiation functionality, which have been leveraged numerous strategies promote formation long-lasting memory cells with stem-like properties supercharging performance. This review highlights transcriptional factors, such as c-Jun FOXO1, enhance sustain effector function, diminishes exhaustion, regulators like TET2 DNMT3A, whose knockout promotes subsets formation. We explore their interconnections, downstream targets, biological impacts, potential application risks certain candidates, providing a comprehensive theoretical framework therapies through interventions.

Language: Английский

Citations

0
Towards precision medicine strategies using plasma proteomic profiling for suspected gallbladder cancer: a pilot study DOI Creative Commons
Ghada Nouaïria, Martin Cornillet, Hannes Jansson

et al.

JHEP Reports, Journal Year: 2025, Volume and Issue: unknown, P. 101365 - 101365

Published: Feb. 1, 2025

Language: Английский

Citations

0
STAT3 Signaling Pathway in Health and Disease DOI Creative Commons
Md Abdus Samad, Iftikhar Ahmad, A. M. Mahedi Hasan

et al.

MedComm, Journal Year: 2025, Volume and Issue: 6(4)

Published: March 30, 2025

ABSTRACT Signal transducer and activator of transcription 3 (STAT3) is a critical factor involved in multiple physiological pathological processes. While STAT3 plays an essential role homeostasis, its persistent activation has been implicated the pathogenesis various diseases, particularly cancer, bone‐related autoimmune disorders, inflammatory cardiovascular neurodegenerative conditions. The interleukin‐6/Janus kinase (JAK)/STAT3 signaling axis central to activation, influencing tumor microenvironment remodeling, angiogenesis, immune evasion, therapy resistance. Despite extensive research, precise mechanisms underlying dysregulated disease progression remain incompletely understood, no United States Food Drug Administration (USFDA)‐approved direct inhibitors currently exist. This review provides comprehensive evaluation STAT3's health disease, emphasizing involvement cancer stem cell maintenance, metastasis, inflammation, drug We systematically discuss therapeutic strategies, including JAK (tofacitinib, ruxolitinib), Src Homology 2 domain (S3I‐201, STATTIC), antisense oligonucleotides (AZD9150), nanomedicine‐based delivery systems, which enhance specificity bioavailability while reducing toxicity. By integrating molecular mechanisms, pathology, emerging interventions, this fills knowledge gap STAT3‐targeted therapy. Our insights into crosstalk, epigenetic regulation, resistance offer foundation for developing next‐generation with greater clinical efficacy translational potential.

Language: Английский

Citations

0
B3GNT5 is a novel marker correlated with malignant phenotype and poor outcome in pancreatic cancer DOI Creative Commons
Wei Yao, Yihui Wang, Xin Zhang

et al.

iScience, Journal Year: 2024, Volume and Issue: 27(10), P. 110889 - 110889

Published: Sept. 6, 2024

Language: Английский

Citations

1
Dissecting Out a Rare Mutation, STAT: Features of STAT3-Mutant Myeloid Neoplasms DOI
Michael J. Hochman, David A. Frank

Clinical Cancer Research, Journal Year: 2024, Volume and Issue: 30(20), P. 4554 - 4556

Published: Aug. 7, 2024

The transcription factor STAT3 drives the expression of genes promoting cellular proliferation, survival, and pluripotency. description mutations their clinical correlates in myeloid neoplasms, such as acute leukemia myelodysplastic syndromes, raises new insights into both pathogenesis targeted therapy these diseases. See related article by Ye et al., p. 4681.

Language: Английский

Citations

0